Physician profile
John M Otto
NPI 1992783716
$663.94
in general payments reported to CMS, 2019-2025
9 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.72 · 2022: $139 · 2023: $126 · 2024: $184 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $237.00 | 2020-2025 | Rocklatan, Clareon, Simbrinza |
| Bausch & Lomb Americas INC. | $140.45 | 2023-2025 | Vyzulta, Envista Envy Iol, Miebo |
| Abbvie INC. | $76.49 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $67.74 | 2024 | Xdemvy |
| Dompe US, INC. | $56.16 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $25.92 | 2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $22.83 | 2024 | Catalys System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.95 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.